{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T16:39:41Z","timestamp":1783960781836,"version":"3.55.0"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"44","license":[{"start":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T00:00:00Z","timestamp":1604016000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background\/Aim:<\/jats:title>\n            <jats:p>Proton pump inhibitor (PPI) alone is not satisfactory for the treatment of gastroesophageal reflux disease (GERD). Therefore, we investigated the efficacy of DA-5204 (Stillen 2X, 90\u200amg of <jats:italic toggle=\"yes\">Artemisia asiatica<\/jats:italic> 95% ethanol extract per tablet) and PPI combination therapy on GERD in comparison to PPI alone.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This randomized, double-blind, placebo-controlled study randomly assigned 70 patients with endoscopically proven esophageal mucosal injury (Los Angeles classification grade A or B) into 2 groups: pantoprazole 40\u200amg once daily with DA-5204 twice daily (DA-5204 group) or pantoprazole 40\u200amg once daily with placebo twice daily (placebo group) for 4 weeks. The primary endpoint was endoscopic healing rate. The secondary endpoint was sufficient relief (\u226550% reduction) of symptoms using GERD Questionnaire.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Final analyses included 29 patients with the DA-5204 group and 30 patients with the placebo group. At weeks 4, there was no significant difference in the endoscopic healing rate between the 2 groups (DA-5204 vs placebo; 96.6% vs 93.3%; <jats:italic toggle=\"yes\">P<\/jats:italic> = 1.000). However, the rate of residual minimal change was significantly lower in the DA-5204 group (5\/28, 17.9%) than in the placebo group (17\/28, 60.7%) (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a\n                                 <jats:italic toggle=\"yes\">&lt;<\/jats:italic>\u200a.001). The rates of symptom relief were not different between the DA-5204 group and the placebo group (all <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&gt;\u200a.05).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Combined therapy with PPI and DA-5204 has no additional effect on the endoscopic healing rate compared to PPI alone. However, it may be beneficial in resolving minimal change.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000022729","type":"journal-article","created":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T19:01:53Z","timestamp":1603911713000},"page":"e22729","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy of DA-5204 (Stillen 2X) for patients with gastroesophageal reflux disease"],"prefix":"10.1097","volume":"99","author":[{"given":"Jae Ho","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyuk","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheol Min","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6376-410X","authenticated-orcid":false,"given":"Dong Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,10,30]]},"reference":[{"key":"R1-20230916","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/j.1572-0241.2006.00630.x","article-title":"The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus","volume":"101","author":"Vakil","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"R2-20230916","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00535-016-1227-8","article-title":"Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015","volume":"51","author":"Iwakiri","year":"2016","journal-title":"J Gastroenterol"},{"key":"R3-20230916","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.3748\/wjg.v19.i39.6523","article-title":"Gastroesophageal reflux disease: update on inflammation and symptom perception","volume":"19","author":"Altomare","year":"2013","journal-title":"World J Gastroenterol"},{"key":"R4-20230916","first-page":"93","article-title":"Endoscopic evaluation of gastro-esophageal reflux disease","volume":"72","author":"Armstrong","year":"1999","journal-title":"Yale J Biol Med"},{"key":"R5-20230916","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000219365","article-title":"Diagnosis and management of non-erosive reflux disease--the Vevey NERD Consensus Group","volume":"80","author":"Modlin","year":"2009","journal-title":"Digestion"},{"key":"R6-20230916","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1572-0241.2005.41217.x","article-title":"Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease","volume":"100","author":"DeVault","year":"2005","journal-title":"Am J Gastroenterol"},{"issue":"(Suppl)","key":"R7-20230916","first-page":"39","article-title":"An evaluation of current GERD therapy: a summary and comparison of effectiveness, adverse effects and costs of drugs, surgery and endoscopic therapy","volume":"18","author":"Katelaris","year":"2004","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"(Suppl 5)","key":"R8-20230916","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.3949\/ccjm.70.Suppl_5.S33","article-title":"The continuum of GERD complications","volume":"70","author":"Fennerty","year":"2003","journal-title":"Cleve Clin J Med"},{"key":"R9-20230916","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/gut.2004.051821","article-title":"Epidemiology of gastro-oesophageal reflux disease: a systematic review","volume":"54","author":"Dent","year":"2005","journal-title":"Gut"},{"key":"R10-20230916","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1136\/gutjnl-2016-313589","article-title":"Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis","volume":"67","author":"Eusebi","year":"2018","journal-title":"Gut"},{"key":"R11-20230916","doi-asserted-by":"crossref","first-page":"279","DOI":"10.4166\/kjg.2010.55.5.279","article-title":"Diagnosis of gastroesophageal reflux disease: a systematic review","volume":"55","author":"Cho","year":"2010","journal-title":"Korean J Gastroenterol"},{"key":"R12-20230916","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1111\/jgh.12899","article-title":"Prevalence of gastroesophageal reflux disease in children, adults, and elderly in the same community","volume":"30","author":"Okimoto","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"R13-20230916","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/MCG.0000000000000304","article-title":"Gastroesophageal reflux disease: cross-sectional study demonstrating rising prevalence in a chinese population","volume":"50","author":"Tan","year":"2016","journal-title":"J Clin Gastroenterol"},{"key":"R14-20230916","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s00535-009-0047-5","article-title":"Epidemiology and clinical characteristics of GERD in the Japanese population","volume":"44","author":"Fujiwara","year":"2009","journal-title":"J Gastroenterol"},{"key":"R15-20230916","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.cgh.2005.10.011","article-title":"Systematic review on epidemiology of gastroesophageal reflux disease in Asia","volume":"4","author":"Wong","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R16-20230916","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/ajg.2012.444","article-title":"Guidelines for the diagnosis and management of gastroesophageal reflux disease","volume":"108","author":"Katz","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"R17-20230916","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1046\/j.1365-2036.1997.00167.x","article-title":"Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials","volume":"11","author":"Carlsson","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"R18-20230916","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1053\/gast.1997.v112.pm9178669","article-title":"Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis","volume":"112","author":"Chiba","year":"1997","journal-title":"Gastroenterology"},{"key":"R19-20230916","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2036.1995.tb00347.x","article-title":"A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Multicentre Investigational Group","volume":"9","author":"Robinson","year":"1995","journal-title":"Aliment Pharmacol Ther"},{"key":"R20-20230916","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/BF01798351","article-title":"Omeprazole (40\u200amg) is superior to ranitidine in short-term treatment of ulcerative reflux esophagitis","volume":"33","author":"Vantrappen","year":"1988","journal-title":"Dig Dis Sci"},{"key":"R21-20230916","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-2036.2005.02531.x","article-title":"Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease--where next?","volume":"22","author":"Fass","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"R22-20230916","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/gut.49.3.364","article-title":"Oxidative stress is more important than acid in the pathogenesis of reflux oesophagitis in rats","volume":"49","author":"Oh","year":"2001","journal-title":"Gut"},{"key":"R23-20230916","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.3748\/wjg.v10.i16.2379","article-title":"DA-9601 for erosive gastritis: results of a double-blind placebo-controlled phase III clinical trial","volume":"10","author":"Seol","year":"2004","journal-title":"World J Gastroenterol"},{"key":"R24-20230916","first-page":"573","article-title":"The inhibitory effect of eupatilin on Helicobacter pylori-induced release of leukotriene D4 in the human neutrophils and gastric mucosal cells","volume":"1","author":"Lee","year":"1997","journal-title":"Korean J Physiol Pharmacol"},{"key":"R25-20230916","first-page":"111","article-title":"Studies on antiulcer effects of DA-9601, an Artemisia herba extract against experimental gastric ulcers and its mechanism","volume":"4","author":"Oh","year":"1996","journal-title":"J Appl Pharmacol"},{"key":"R26-20230916","first-page":"202","article-title":"Studies on protective effect of DA-9601, an Artemisiae Herba extract, against ethanol-induced gastric mucosal damage and its mechanism","volume":"5","author":"Lee","year":"1997","journal-title":"J Appl Pharmacol"},{"key":"R27-20230916","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/BF02973932","article-title":"Protective effect of DA-9601, an extract ofArtemisiae Herba, against naproxen-induced gastric damage in arthritic rats","volume":"20","author":"Oh","year":"1997","journal-title":"Arch Pharm Res"},{"key":"R28-20230916","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1111\/j.1365-2036.2009.04142.x","article-title":"Development of the GerdQ, a tool for the diagnosis and management of gastro-oesophageal reflux disease in primary care","volume":"30","author":"Jones","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"R29-20230916","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1053\/gast.1996.v111.pm8698230","article-title":"The endoscopic assessment of esophagitis: a progress report on observer agreement","volume":"111","author":"Armstrong","year":"1996","journal-title":"Gastroenterology"},{"key":"R30-20230916","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1136\/gut.45.2.172","article-title":"Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification","volume":"45","author":"Lundell","year":"1999","journal-title":"Gut"},{"key":"R31-20230916","first-page":"1459","article-title":"Endoscopic findings of GERD","volume":"62","author":"Hoshihara","year":"2004","journal-title":"Nippon Rinsho"},{"key":"R32-20230916","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00535-006-1775-4","article-title":"Minimal changes in reflux esophagitis: red ones and white ones","volume":"41","author":"Hongo","year":"2006","journal-title":"J Gastroenterol"},{"key":"R33-20230916","doi-asserted-by":"crossref","first-page":"91","DOI":"10.5056\/jnm18133","article-title":"Validation of the Korean version of the gastroesophageal reflux disease questionnaire for the diagnosis of gastroesophageal reflux disease","volume":"25","author":"Gong","year":"2019","journal-title":"J Neurogastroenterol Motil"},{"key":"R34-20230916","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j..2002.384.doc.x","article-title":"Design and analysis of pilot studies: recommendations for good practice","volume":"10","author":"Lancaster","year":"2004","journal-title":"J Eval Clin Pract"},{"key":"R35-20230916","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/sim.4780141709","article-title":"On the use of a pilot sample for sample size determination","volume":"14","author":"Browne","year":"1995","journal-title":"Stat Med"},{"key":"R36-20230916","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1365-2036.2009.04077.x","article-title":"Systematic review: standard- and double-dose proton pump inhibitors for the healing of severe erosive oesophagitis -- a mixed treatment comparison of randomized controlled trials","volume":"30","author":"Edwards","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"R37-20230916","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1007\/s10620-012-2297-y","article-title":"Efficacy of S-pantoprazole 20\u200amg compared with pantoprazole 40\u200amg in the treatment of reflux esophagitis: a randomized, double-blind comparative trial","volume":"57","author":"Cho","year":"2012","journal-title":"Dig Dis Sci"},{"key":"R38-20230916","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.3346\/jkms.2017.32.11.1807","article-title":"Evaluation of the efficacy and safety of DA-9601 versus its new formulation, DA-5204, in patients with gastritis: phase III, randomized, double-blind, non-inferiority study","volume":"32","author":"Choi","year":"2017","journal-title":"J Korean Med Sci"},{"key":"R39-20230916","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s11095-008-9531-5","article-title":"Eupatilin protects gastric epithelial cells from oxidative damage and down-regulates genes responsible for the cellular oxidative stress","volume":"25","author":"Choi","year":"2008","journal-title":"Pharm Res"},{"key":"R40-20230916","first-page":"4850","article-title":"DA-9601, a standardized extract of Artemisia asiatica, blocks TNF-alpha-induced IL-8 and CCL20 production by inhibiting p38 kinase and NF-kappaB pathways in human gastric epithelial cells","volume":"12","author":"Choi","year":"2006","journal-title":"World J Gastroenterol"},{"key":"R41-20230916","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0378-8741(03)00235-6","article-title":"Inhibitory effects of DA-9601 on ethanol-induced gastrohemorrhagic lesions and gastric xanthine oxidase activity in rats","volume":"88","author":"Huh","year":"2003","journal-title":"J Ethnopharmacol"},{"key":"R42-20230916","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/j.1440-1746.2008.05380.x","article-title":"Gastroesophageal reflux disease in Asia: a condition in evolution","volume":"23","author":"Ho","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"key":"R43-20230916","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1440-1746.2004.03419.x","article-title":"Report of the Asia-Pacific consensus on the management of gastroesophageal reflux disease","volume":"19","author":"Fock","year":"2004","journal-title":"J Gastroenterol Hepatol"},{"issue":"(Suppl 2)","key":"R44-20230916","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2036.2005.02469.x","article-title":"Minimal change oesophagitis: a disease with characteristic differences to erosive oesophagitis","volume":"21","author":"Nakamura","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"R45-20230916","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/s00535-007-2022-3","article-title":"Validity of endoscopic classification of nonerosive reflux disease","volume":"42","author":"Joh","year":"2007","journal-title":"J Gastroenterol"},{"key":"R46-20230916","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1159\/000337198","article-title":"Prevalence of minimal change lesions in patients with non-erosive reflux disease: a case-control study","volume":"85","author":"Kim","year":"2012","journal-title":"Digestion"},{"key":"R47-20230916","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000080323","article-title":"Minimal change esophagitis: prospective comparison of endoscopic and histological markers between patients with non-erosive reflux disease and normal controls using magnifying endoscopy","volume":"22","author":"Kiesslich","year":"2004","journal-title":"Dig Dis"},{"key":"R48-20230916","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-2006-945112","article-title":"Magnification endoscopy for diagnosis of nonerosive reflux disease: a proposal of diagnostic criteria and critical analysis of observer variability","volume":"39","author":"Edebo","year":"2007","journal-title":"Endoscopy"},{"key":"R49-20230916","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/j.1572-0241.2007.01688.x","article-title":"Esophageal dilated intercellular spaces (DIS) and nonerosive reflux disease","volume":"103","author":"van Malenstein","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"(Suppl 1)","key":"R50-20230916","first-page":"A16","article-title":"Esophageal mucosal damage induced by weakly acidic solutions containing unconjugated bile acids, similar to reflux in GERD patients \u201con\u201d PPI, can be prevented with anti-oxidants [abstr]","volume":"136","author":"Farre","year":"2009","journal-title":"Gastroenterology"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000022729","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T01:56:28Z","timestamp":1694829388000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000022729"}},"subtitle":["A randomized, double-blind, placebo-controlled pilot study"],"short-title":[],"issued":{"date-parts":[[2020,10,30]]},"references-count":50,"journal-issue":{"issue":"44","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000022729","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,30]]}}}